Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FHD-286 + Revumenib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FHD-286 | FHD286|FHD 286 | FHD-286 inhibits SMARCA4 (BRG1) and SMARCA2 (BRM), which may lead to altered chromatin accessibility and decreased tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr ND14, PMID: 38437498). | ||
Revumenib | Revuforj | SNDX5613|SNDX 5613|SNDX-5613 | MEN1-KMT2A Inhibitor 8 | Revuforj (revumenib) inhibits the interaction between Menin and KMT2A (MLL), potentially resulting in antitumor activity and decreased proliferation of tumor cells with KMT2A (MLL) rearrangements or NPM1 mutations (PMID: 36922593, PMID: 36922589). Revuforj (revumenib) is FDA-approved for use in adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia harboring KMT2A translocation (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | acute myeloid leukemia | sensitive | FHD-286 + Revumenib | Preclinical - Patient cell culture | Actionable | In a preclinical study, the combination of FHD-286 and Revuforj (revumenib) synergistically inhibited viability of acute myeloid leukemia cell lines and a patient-derived cell line harboring a KMT2A rearrangement in culture (PMID: 38437498). | 38437498 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|